Lonza starts manufacturing from cGMP viral immunotherapy suites
Completes validation in Houston, Texas
Lonza has completed the validation of its new viral-induced cell processing GMP suites in Houston, Texas and the technology transfer process for a new virally transfected T-cell product.
The cleanroom supports multiple types of viral vector and viral vaccine projects, with working volumes up to 2,000 litres.
Last year the Swiss supplier to the pharmaceutical industry announced the expansion of its GMP facilities in Houston so that it could better serve the needs of customers. With the addition of these cell-processing suites, Lonza can now serve clients developing virally modified autologous cellular immunotherapies, which the company says is a rapidly growing segment in regenerative medicine.
‘We are pleased to have been selected by our existing viral vector client to additionally perform the development and manufacture of virally-modified cellular products to support its clinical studies,’ said David Enloe, Lonza’s Head of Viral-based Therapeutics.
‘Lonza is a leader in the contract manufacture of protein, cell, and virus-based products. As the field of regenerative medicine expands to include combination products, we are pleased to grow with the field and offer seamless contract manufacturing services for the development and manufacture of these unique products.’